Search

Your search keyword '"Sosnowski, M"' showing total 607 results
Start Over Author "Sosnowski, M"
607 results on '"Sosnowski, M"'

39. The role of selected egzo- and endogenic agents on preinitiation process of bladder cancer

Author

Iwaniuk, A, Owczarek, M, PietrusiÅski, M, Borkowska, E, Rozniecki, M, Borowiec, M, Sosnowski, M, Kocki, J, and KaÅużewski, B

Subjects
ewski, B, ewski, Bladder cancer -- Genetic aspects -- Development and progression, Genotype -- Health aspects -- Genetic aspects, Health
Abstract

Author(s): A Iwaniuk[sup.1] , M Owczarek[sup.1] , M PietrusiÅski[sup.2] , E Borkowska[sup.2] , M Rozniecki[sup.5] , M Borowiec[sup.2] , M Sosnowski[sup.3] , J Kocki[sup.4] and B KaÅużewski[sup.1] The pilot study [...]

Published
2015
Full Text
View/download PDF

42. Traffic management for Cloud Federation

Author

Burakowski, W., Beben, A., Ber, J.L. van den, Bosman, J.W., Hasslinger, G., Kertesz, A., Latre, S., Mei, R. van der, Pflanzner, T., Poullie, P.G., Sosnowski, M., Spinnewyn, B., and Stiller, B.

Subjects
Multi-layer model, Cloud federations, Computer. Automation, Artificial intelligence, Service composition, Quality of service, Traffic management, Cloud federation, Service provision, Computer science, Engineering sciences. Technology
Abstract

The chapter summarizes activities of COST IC1304 ACROSS European Project corresponding to traffic management for Cloud Federation (CF). In particular, we provide a survey of CF architectures and standardization activities. We present comprehensive multi-level model for traffic management in CF that consists of five levels: Level 5 - Strategies for building CF, Level 4 - Network for CF, Level 3 - Service specification and provision, Level 2 - Service composition and orchestration, and Level 1 - Task service in cloud resources. For each level we propose specific methods and algorithms. The effectiveness of these solutions were verified by simulation and analytical methods. Finally, we also describe specialized simulator for testing CF solution in IoT environment.

Published
2018

46. Traffic management for cloud federation

Author

Burakowski, W. (Wojciech), Beben, A. (Andrzej), Berg, J.L. (Hans) van den, Bosman, J.W. (Joost), Hasslinger, G. (Gerhard), Kertesz, A. (Attila), Latre, S. (Steven), Mei, R.D. (Rob) van der, Pflanzner, T. (Tamas), Poullie, P.G. (Patrick Gwydion), Sosnowski, M. (Maciej), Spinnewyn, B. (Bart), Stiller, B. (Burkhard), Burakowski, W. (Wojciech), Beben, A. (Andrzej), Berg, J.L. (Hans) van den, Bosman, J.W. (Joost), Hasslinger, G. (Gerhard), Kertesz, A. (Attila), Latre, S. (Steven), Mei, R.D. (Rob) van der, Pflanzner, T. (Tamas), Poullie, P.G. (Patrick Gwydion), Sosnowski, M. (Maciej), Spinnewyn, B. (Bart), and Stiller, B. (Burkhard)

Abstract

The chapter summarizes activities of COST IC1304 ACROSS European Project corresponding to traffic management for Cloud Federation (CF). In particular, we provide a survey of CF architectures and standardization activities. We present comprehensive multi-level model for traffic management in CF that consists of five levels: Level 5 - Strategies for building CF, Level 4 - Network for CF, Level 3 - Service specification and provision, Level 2 - Service composition and orchestration, and Level 1 - Task service in cloud resources. For each level we propose specific methods and algorithms. The effectiveness of these solutions were verified by simulation and analytical methods. Finally, we also describe specialized simulator for testing CF solution in IoT environment.

Published
2018
Full Text
View/download PDF

47. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Author

Ravaud, A, Motzer, Rj, Pandha, Hs, George, Dj, Pantuck, Aj, Patel, A, Chang, Yh, Escudier, B, Donskov, F, Magheli, A, Carteni, G, Laguerre, B, Tomczak, P, Breza, J, Gerletti, P, Lechuga, M1, Lin, X, Martini, Jf, Ramaswamy, K, Casey, M, Staehler, M, Patard, Jj, Gruenwald, V, Link, K, Doehn, C, Heinzer, H, Grimm, M-O, Wirth, M, Stoeckle, M, Heidenreich, A, Garcia del Muro Solans, X, Mellado, Bo, Castellano, Dg, Frydenberg, M, Schobinger, Sr, Dimopoulos, Ma, Rothermundt, C, Climent Duran MA, Melotti, B, Procopio, G, Boccardo, F, Sella, A, Stewart, S, Adenis, A, Jones, Rj, Chevreau, C, Prausova, J, Vyzula, R, Oudard, S, Jacqmin, D, Gravis, G, Varela, R, Herrmann, E, Lim, Hy, Lee, J-L, Kim, Yh, Kim, Jh, Y-C, Ou, Papakotoulas, P, Iacobelli, S, Chowdhury, S, Passalacqua, R, Tomasek, J, Anton Aparicio LM, Linassier, C, Hauser, S, Bergmann, L, Hawkins, Re, Szczylik, C, Zdrojowy, R, Sosnowski, M, Koralewski, P, Wiechnio, Pj, Schraml, J, Mardiak, J, Laurinc, P, Kliment, J, Rosenbaum, E, Lundstam, S, Flodgren, P, Ljungberg, B, Stenzl, A, Schnoeller, Tj, Mcdermott, Sr, Breathnach, Os, Mccaffrey, Ja, Donnellan, P, The, G-C, Rolland, F, Brekkan, E, Nilsson, C, Kim, Wy, Bishoff, J, Chung, J, Shore, Nd, Master, V, Tang Chen DY, Ye, D, Huang, Y, Jin, J, Song, B, Zhou, F, Galceran, Jc, Yao, X, and Zhang, X.

Subjects
Male, Indoles, medicine.medical_treatment, Clinical Trial, Phase III, 030232 urology & nephrology, Nephrectomy, 0302 clinical medicine, Renal cell carcinoma, Clinical endpoint, 80 and over, Adjuvant, Aged, 80 and over, Adolescent, Adult, Aged, Antineoplastic Agents, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Double-Blind Method, Drug Administration Schedule, Female, Humans, Kidney Neoplasms, Middle Aged, Pyrroles, Survival Analysis, Young Adult, Medicine (all), Sunitinib, General Medicine, Multicenter Study, 030220 oncology & carcinogenesis, Randomized Controlled Trial, medicine.drug, medicine.medical_specialty, Urology, Placebo, 03 medical and health sciences, Journal Article, Carcinoma, medicine, Chemotherapy, Survival analysis, business.industry, Renal Cell, medicine.disease, Surgery, Clinical trial, business
Abstract

BACKGROUNDSunitinib, a vascular endothelial growth factor pathway inhibitor, is an effectivetreatment for metastatic renal-cell carcinoma. We sought to determine the efficacyand safety of sunitinib in patients with locoregional renal-cell carcinoma athigh risk for tumor recurrence after nephrectomy.METHODSIn this randomized, double-blind, phase 3 trial, we assigned 615 patients withlocoregional, high-risk clear-cell renal-cell carcinoma to receive either sunitinib(50 mg per day) or placebo on a 4-weeks-on, 2-weeks-off schedule for 1 year oruntil disease recurrence, unacceptable toxicity, or consent withdrawal. The primaryend point was disease-free survival, according to blinded independent central review.Secondary end points included investigator-assessed disease-free survival,overall survival, and safety.RESULTSThe median duration of disease-free survival was 6.8 years (95% confidence interval[CI], 5.8 to not reached) in the sunitinib group and 5.6 years (95% CI, 3.8 to6.6) in the placebo group (hazard ratio, 0.76; 95% CI, 0.59 to 0.98; P=0.03). Overallsurvival data were not mature at the time of data cutoff. Dose reductions becauseof adverse events were more frequent in the sunitinib group than in theplacebo group (34.3% vs. 2%), as were dose interruptions (46.4% vs. 13.2%) anddiscontinuations (28.1% vs. 5.6%). Grade 3 or 4 adverse events were more frequentin the sunitinib group (48.4% for grade 3 events and 12.1% for grade 4 events)than in the placebo group (15.8% and 3.6%, respectively). There was a similarincidence of serious adverse events in the two groups (21.9% for sunitinib vs.17.1% for placebo); no deaths were attributed to toxic effects.CONCLUSIONSAmong patients with locoregional clear-cell renal-cell carcinoma at high risk fortumor recurrence after nephrectomy, the median duration of disease-free survivalwas significantly longer in the sunitinib group than in the placebo group, at a costof a higher rate of toxic events. (Funded by Pfizer; S-TRAC ClinicalTrials.gov number,NCT00375674.)

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results